Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.38 +0.1%	$2.62	$1.11 ▼ $10.54	$46.18M	1.51	262,847 shs	346,257 shs
ATNM Actinium Pharmaceuticals	$1.74 +1.8%	$1.59	$1.03 ▼ $2.41	$53.35M	-0.53	413,994 shs	122,957 shs
KPTI Karyopharm Therapeutics	$6.30 +4.7%	$4.53	$3.51 ▼ $16.95	$54.63M	0.28	201,302 shs	112,192 shs
ME 23andMe	$0.50 -35.3%	$0.50	$0.53 ▼ $9.57	$13.36M	1.19	1.57 million shs	29.28 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+0.08%	-12.75%	-9.60%	+19.70%	-75.21%
ATNM Actinium Pharmaceuticals	+1.75%	+2.96%	-6.95%	+6.10%	-17.92%
KPTI Karyopharm Therapeutics	+4.65%	+6.42%	+29.63%	+37.25%	-48.10%
ME 23andMe	0.00%	0.00%	0.00%	0.00%	-92.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	2.5185 of 5 stars	3.3	3.0	0.0	0.0	2.1	1.7	0.6
ATNM Actinium Pharmaceuticals	2.9839 of 5 stars	3.5	5.0	0.0	0.0	2.8	0.0	0.6
KPTI Karyopharm Therapeutics	3.8169 of 5 stars	3.4	0.0	0.0	4.6	2.0	2.5	0.6
ME 23andMe	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.60	Moderate Buy	$18.00	655.67% Upside
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	158.62% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	439.68% Upside
ME 23andMe	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ME, ANVS, ATNM, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
8/8/2025	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.94 per share	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.38	N/A	N/A	($27.55) per share	-0.23
ME 23andMe	$208.78M	0.06	$0.54 per share	0.93	$2.34 per share	0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.04	N/A	N/A	N/A	N/A	-206.01%	-158.26%	N/A
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.31	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)
ME 23andMe	-$666.70M	-$15.45	N/A	∞	N/A	-183.39%	-170.07%	-62.13%	N/A

Latest ME, ANVS, ATNM, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	ANVS Annovis Bio	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
ME 23andMe	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	7.65	7.65
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
KPTI Karyopharm Therapeutics	N/A	0.99	0.94
ME 23andMe	N/A	1.05	0.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
ATNM Actinium Pharmaceuticals	27.50%
KPTI Karyopharm Therapeutics	66.44%
ME 23andMe	36.10%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
ATNM Actinium Pharmaceuticals	6.00%
KPTI Karyopharm Therapeutics	2.98%
ME 23andMe	26.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable
ME 23andMe	770	26.83 million	19.77 million	Not Optionable

ME, ANVS, ATNM, and KPTI Headlines

Recent News About These Companies

23andMe Board Approves Changes to CEO’s Compensation

August 22 at 4:50 PM | tipranks.com

Why Ancestry Is the Best DNA Test Kit in 2025

August 21 at 8:40 AM | cnet.com

23andMe Holding Finalizes Asset Sales Amid Bankruptcy

August 19, 2025 | msn.com

The Family Fallout of DNA Surprises

August 18, 2025 | newyorker.comN

A 1974 murder rocked a small Pittsburgh suburb. Police just found the woman’s killer using a 23andMe-like clue

August 17, 2025 | yahoo.com

23andMe Rebrands to Chrome Holding Co.

August 15, 2025 | tipranks.com

They’ve Got Next: The 40 Under 40 - Evan Hill of Cravath, Swaine & Moore

August 13, 2025 | news.bloomberglaw.comN

'I took a DNA test and discovered devastating truth my family hid for 24 years'

August 10, 2025 | mirror.co.ukM

Genetics of Stuttering: Why It is More Than a Speech Disorder

August 9, 2025 | msn.com

Woman claims 23andMe test proves she’s the daughter of influential sculptor Fred Eversley

August 9, 2025 | msn.com

Claire's files second bankruptcy petition in 7 years

August 6, 2025 | msn.com

‘Protect your genetic data’: Court approves sale of 23andMe assets, including genetic samples

July 31, 2025 | msn.com

Utah AG issues consumer advisory for 23andMe customers

July 31, 2025 | yahoo.com

Largest genetic study confirms biological basis of stuttering

July 29, 2025 | msn.com

Largest genetic study links stuttering to 57 distinct genomic regions

July 28, 2025 | msn.com

23andMe Sale Update

July 25, 2025 | jdsupra.com

Rep. Cline cosponsors bill to protect genetic privacy

July 25, 2025 | msn.com

23andMe Ombudsman Beats DOJ Pushback in Bid to Hire WilmerHale

July 23, 2025 | news.bloomberglaw.comN

23andMe Bankruptcy: The Privacy Ombudsman’s Report

July 18, 2025 | jdsupra.com

23andMe Bankruptcy Update: How the Proceedings Highlight Best Practices for Handling and Transferring Genetic Data and Personal Information

July 18, 2025 | jdsupra.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ME, ANVS, ATNM, and KPTI Company Descriptions

Annovis Bio NYSE:ANVS

$2.38 +0.00 (+0.08%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$2.38 0.00 (-0.08%)

As of 08/22/2025 07:58 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Actinium Pharmaceuticals NYSE:ATNM

$1.74 +0.03 (+1.75%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.74 0.00 (-0.29%)

As of 08/22/2025 07:33 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Karyopharm Therapeutics NASDAQ:KPTI

$6.30 +0.28 (+4.65%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.38 +0.08 (+1.27%)

As of 08/22/2025 07:50 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

23andMe NASDAQ:ME

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time